ArticleNature2022
RASA2 ablation in T cells boosts antigen sensitivity and long-term function.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
162citing papers in PubMed, 2 pooled it
21.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
162 citing papers in PubMed, 2 syntheses or guidelines pooled it, 207 citations in OpenAlex.
- Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Pooled it
- Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions.Science China. Life sciences · 2026Pooled it
- Trial
- DNA Methylation of BDNF and RASA2 Genes Is Associated With Cognitive Function in Postmenopausal Women With Breast Cancer.Oncology nursing forum · 2024Trial
- Article
- Article
- SPRED2 Negatively Regulates CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma.Cell reports. Medicine · 2026Article
- Integrated epigenetic and genetic programming of primary human T cells.Nature biotechnology · 2026Article
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
- Article
- Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells.Nature biotechnology · 2026Article
- Surfaceome CRISPR activation screening uncovers ligands regulating tumor sensitivity to NK cell killing.Nature communications · 2026Article
- Decoding immunotherapy resistance in multiple myeloma: genetic insights and approaches to counter resistance.Science China. Life sciences · 2026Review
- The ageing immune system and its battle with viruses.The Journal of general virology · 2026Review
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- Segmentation-free analysis of live-cell imaging data reveals how T cell modifications influence cancer cell aggregation dynamics.Scientific reports · 2026Article
- Peptide-MHC-targeted engineered virus-like particles enable selective priming and gene editing of tumor-specific T cells.Cell reports · 2026Article
102 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
33 authors at 5 institutions in 3 countries.
Julia Carnevale *Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. julia.carnevale@ucsf.edu.ORCID http://orcid.org/0000-0001-9410-7148
Eric Shifrut *Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. eric.shifrut@ucsf.edu.ORCID http://orcid.org/0000-0001-6827-0128
Nupura KaleDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3185-8646
William A NybergGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Franziska BlaeschkeGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5770-4744
Yan Yi ChenGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-3611-2621
Zhongmei LiGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Sagar P BapatDiabetes Center, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-4402-1511
Morgan E DiolaitiUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5900-3060
Patrick O'LearyUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-2919-5943
Shane VedovaGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Julia BelkDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-4724-6158
Bence DanielDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-2410-8767
Theodore L RothDepartment of Pathology, Stanford University, Stanford, CA, USA.
Stefanie BachlGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Alejandro Allo AnidoDepartment of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN, USA.
Brooke PrinzingDepartment of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN, USA.
Jorge Ibañez-VegaDepartment of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN, USA.
Shannon LangeDepartment of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN, USA.
Dalia HaydarDepartment of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN, USA.
Marie Luetke-EverslohDepartment of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN, USA.
Maelys Born-BonyDepartment of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN, USA.
Bindu HegdeUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Scott KoganUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-2395-8479
Tobias FeuchtingerDepartment of Pediatric Hematology, Oncology and Stem Cell Transplantation, Dr von Hauner Children's Hospital, University Hospital, LMU, Munich, Germany.ORCID http://orcid.org/0000-0002-8517-9681
Hideho OkadaUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-0076-9920
Ansuman T SatpathyGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5167-537X
Kevin ShannonDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-4299-1773
Stephen GottschalkDepartment of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0003-3991-7468
Justin EyquemGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. Justin.Eyquem@ucsf.edu.ORCID http://orcid.org/0000-0001-8262-1190
Giedre KrenciuteDepartment of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN, USA. giedre.krenciute@stjude.org.ORCID http://orcid.org/0000-0003-4335-0644
Alan AshworthDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA. alan.ashworth@ucsf.edu.ORCID http://orcid.org/0000-0003-1446-7878
Alexander MarsonGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. alexander.marson@ucsf.edu.ORCID http://orcid.org/0000-0002-2734-5776
Gladstone Institutes · USSt. Jude Children's Research Hospital · USUniversity of California, San Francisco · USStanford University · USLudwig-Maximilians-Universität München · DE
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Leigh Clarke · 1999 to 2026
$209.7MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MMolecular and Cellular Mechanisms in CancerT32CA108462 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2004 to 2024
$10.4MPreclinical development of breakthrough immunotherapy for brain tumorsR35NS105068 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKADA, HIDEHO · 2018 to 2025
$6.0MReprogramming of T cells for the Treatment of MelanomaR01CA173750 · NCI · DANA-FARBER CANCER INST · PI GOTTSCHALK, STEPHEN, WUCHERPFENNIG, KAI W · 2012 to 2016
$5.0MGenetic Approaches to Optimize CAR T cells for Glioblastoma TherapyR01NS106379 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BALYASNIKOVA, IRINA V, GOTTSCHALK, STEPHEN · 2018 to 2022
$2.7MImproving genetically engineered T cells for medulloblastomasR01NS121249 · NINDS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI KRENCIUTE, GIEDRE · 2021 to 2025
$2.2MTargeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.K08CA252605 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CARNEVALE, JULIA C · 2020 to 2024
$1.3MImproving CAR T cell therapy for brain tumors using immune competent modelsR00CA256262 · NCI · CHILDREN'S RESEARCH INSTITUTE · PI HAYDAR, DALIA · 2023 to 2025
$713kAcquisition of Covaris E220 and Sciclone G3 systems for high throughput sequencinS10OD010786 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI COMAI, LUCA · 2012 to 2012
$311kImproving CAR T cell therapy for brain tumors using immune competent modelsK99CA256262 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HAYDAR, DALIA · 2021 to 2022
$250kNCI NIH HHS K08 CA252605NCI NIH HHS K99 CA256262NCI NIH HHS P30 CA021765NCI NIH HHS P30 CA082103NCI NIH HHS R00 CA256262NCI NIH HHS R01 CA173750NCI NIH HHS T32 CA108462NIH HHS S10 OD010786NINDS NIH HHS R01 NS106379NINDS NIH HHS R01 NS121249NINDS NIH HHS R35 NS105068Wellcome Trust
Abstract
The efficacy of adoptive T cell therapies for cancer treatment can be limited by suppressive signals from both extrinsic factors and intrinsic inhibitory checkpoints
Indexed as
Antigens, NeoplasmNeoplasmsras GTPase-Activating ProteinsT-LymphocytesAnimalsBone MarrowCRISPR-Cas SystemsDisease Models, AnimalGene Knockdown TechniquesHumansImmunotherapy, AdoptiveLeukemiaMiceReceptors, Antigen, T-CellReceptors, Chimeric AntigenTime FactorsAntigens, NeoplasmRASA2 protein, humanras GTPase-Activating ProteinsReceptors, Antigen, T-CellReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.